

Summary of the Policy Alignment Assessment checklist

Name of Organisation: Valeant Pharmaceutical

Date: November 1st 2016

Tier: 1 Pharmaceutical and weight management products

Brief description of engagement: High and medium risk categories

	Assessment
1. Is the organisation directly connected with therapies or products which are claimed to benefit the health of overweight or obese people, and is there reasonable evidence for the claimed benefit or is there evidence of harm?	Produces pharmaceuticals including Mysimba for weight management (includes naltrexone and bupropion, to reduce appetite and increase energy expenditure). Has European Medicines Agency approval for overweight and obesity, but with additional monitoring required. Some concerns of side-effects (see e.g. PMID: 26594724).
2. Is there reasonable evidence that the company has marketing /advertising strategies or undertakes lobbying or attempts political influence which may be deemed inconsistent or contradictory to World Obesity's advocacy positions or the positions of international bodies with which World Obesity is in official relations (e.g. the World Health Organization)?	No evidence found.
3. Are there any known organizations, bodies or campaigns being funded by the company which might be deemed inconsistent or contradictory to World Obesity's advocacy positions or the positions of international bodies with which World Obesity is in official relations (e.g. the World Health Organization)?	No evidence found.
4. Is there reasonable evidence the company is failing on ethical criteria, e.g. child labour and employee welfare practices; environmental and sustainability practices; human right practices, or that in contrast it has good practices in place?	US Justice Dept investigation of CEO and CFO for possible fraud / price manipulating practices (ongoing at 1 Nov 2016).
5. Does the company have a close business relationship with other commercial interests (e.g. subsidiary or parent company) that should be taken into account in the assessment of risk?	Linked to many companies and brands – see http://www.valeant.eu/our-assets/ - but none of them are known to be a risk to World Obesity conflicts of interest.
6. Are there other matters which might cause reputational damage or a conflict of interest? Are there any known concerns about the company's probity or reputation?	No evidence found, apart from price-fixing concerns (see para 4 above).